Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Pharma (IGC) over the last 16 years, with Q3 2025 value amounting to -$303000.0.

  • Pharma's Change in Account Payables fell 1505000.0% to -$303000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$142000.0, marking a year-over-year decrease of 16454.55%. This contributed to the annual value of $106000.0 for FY2025, which is 5637.86% down from last year.
  • According to the latest figures from Q3 2025, Pharma's Change in Account Payables is -$303000.0, which was down 1505000.0% from $51000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Change in Account Payables peaked at $1.2 million during Q1 2022, and registered a low of -$613000.0 during Q4 2021.
  • In the last 5 years, Pharma's Change in Account Payables had a median value of $44000.0 in 2025 and averaged $48578.9.
  • Within the past 5 years, the most significant YoY rise in Pharma's Change in Account Payables was 265000.0% (2025), while the steepest drop was 1505000.0% (2025).
  • Over the past 5 years, Pharma's Change in Account Payables (Quarter) stood at -$613000.0 in 2021, then skyrocketed by 103.1% to $19000.0 in 2022, then surged by 415.79% to $98000.0 in 2023, then tumbled by 32.65% to $66000.0 in 2024, then plummeted by 559.09% to -$303000.0 in 2025.
  • Its Change in Account Payables stands at -$303000.0 for Q3 2025, versus $51000.0 for Q2 2025 and $44000.0 for Q1 2025.